Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 17/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 17/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 17/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 17/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 17/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 17/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 17/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 17/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 17/20 | 0.48 |
| ▸ | HDAC9 | Q9UKV0 | 17/20 | 0.48 |
| ▸ | HDAC5 | Q9UQL6 | 17/20 | 0.48 |
| ▸ | KDR | P35968 | 16/20 | 0.48 |
| ▸ | EGFR | P00533 | 2/20 | 0.46 |
| ▸ | RET | P07949 | 1/20 | 0.46 |
| ▸ | KIF5B | P33176 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL535751 | 0.84 | HDAC3 (0.48) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL13310097 | 0.80 | RET (0.47) | KDREGFRRETKIF5B | |
| SCHEMBL13310108 | 0.77 | KDR (0.50) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL535675 | 0.76 | KDR (0.48) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL14765531 | 0.76 | SRC (0.52) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL535716 | 0.76 | KDR (0.48) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL535152 | 0.76 | KDR (0.54) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL5237480 | 0.74 | KDR (0.82) | KDREGFRRETKIF5B | |
| SCHEMBL13310075 | 0.74 | KDR (0.47) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL13485444 | 0.74 | SRC (0.51) | KDREGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10208062-B2 | Macrocyclic quinazole derivatives and their use as MTKI | JANSSEN PHARMACEUTICA NV (BE) | 2019-02-19 | — | — | US | disclosed |
| US-20170320894-A1 | MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI | JANSSEN PHARMACEUTICA NV (BE) | 2017-11-09 | — | — | US | disclosed |
| US-20170320894-A1 | MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI | JANSSEN PHARMACEUTICA NV (BE) | 2017-11-09 | — | — | US | disclosed |
| US-9688691-B2 | Macrocyclic quinazole derivatives and their use as MTKI | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-27 | — | — | US | disclosed |
| US-9688691-B2 | Macrocyclic quinazole derivatives and their use as MTKI | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-27 | — | — | US | disclosed |
| US-20140256714-A1 | MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-11 | — | — | US | disclosed |
| US-20140256714-A1 | MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-11 | — | — | US | disclosed |
| US-20100152174-A1 | MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI | JANSSEN-CILAG (FR) | 2010-06-17 | — | — | US | disclosed |
| US-20100152174-A1 | MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI | JANSSEN-CILAG (FR) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256714-A1 | MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI | NR1I3, NR3C2, NR1I2 | HDAC3 193/4885HDAC4 1205/4885HDAC1 450/4885 |
| US-20100152174-A1 | MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI | NR1I3, NR1I2, NR3C2 | HDAC3 143/4885HDAC4 974/4885HDAC1 364/4885 |
| US-20170320894-A1 | MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI | NR1I3, NR3C2, NR1I2 | HDAC3 193/4885HDAC4 1205/4885HDAC1 450/4885 |
| US-10208062-B2 | Macrocyclic quinazole derivatives and their use as MTKI | NR1I3, NR3C2, NR1I2 | HDAC3 193/4885HDAC4 1205/4885HDAC1 450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.